Where does Shenzhen Profound-View Pharma Tech Co., Ltd rank among US patent assignees?

According to USPTO PatentsView (2015–2025 granted utility patents), Shenzhen Profound-View Pharma Tech Co., Ltd ranks #33,285 of 49,997 assignees by granted-patent volume, the same sort as the companies listing and top-holders ranking. See /methodology/#corpus-placement.

How many patents does Shenzhen Profound-View Pharma Tech Co., Ltd hold?

Shenzhen Profound-View Pharma Tech Co., Ltd holds 8 US utility patents granted between 2020 and 2025, spanning 10 technology areas.

What is Shenzhen Profound-View Pharma Tech Co., Ltd's Innovation Score?

Shenzhen Profound-View Pharma Tech Co., Ltd has an Innovation Score of 29.6 out of 100 (31st percentile of the corpus). This composite metric weighs portfolio volume (40%), grant velocity (20%), technology breadth (25%), and claim depth (15%).

What technology areas does Shenzhen Profound-View Pharma Tech Co., Ltd focus on?

Shenzhen Profound-View Pharma Tech Co., Ltd's top technology area is A61P (Specific Therapeutic Activity OF Chemical Compounds OR Medicinal Preparations) with 8 patents, ranking #2,286 of 6,058 assignees active in that subclass. Grants appear in 10 CPC subclasses total.

Is Shenzhen Profound-View Pharma Tech Co., Ltd's patent grant rate increasing or decreasing?

Insufficient historical data is available to calculate a velocity trend for Shenzhen Profound-View Pharma Tech Co., Ltd.

What does claim depth mean for Shenzhen Profound-View Pharma Tech Co., Ltd's patents?

Shenzhen Profound-View Pharma Tech Co., Ltd's patents average 7.0 claims each. This is an aggregate descriptive count from the grant record; it does not establish claim scope, legal strength, enforceability, or design-around risk.

How is the Shenzhen Profound-View Pharma Tech Co., Ltd patent data sourced?

All patent data comes from USPTO PatentsView, a public research dataset maintained by the United States Patent and Trademark Office covering US granted utility patents from 2015 to 2025.

USPTO 2015–2025 USPTO PatentsView Foreign Corporation

Shenzhen Profound-View Pharma Tech Co., Ltd

USPTO PatentsView assignee record - 8 granted patents across 10 technology areas, recorded in grant years 2020–2025. Grant-trend analysis is cross-referenced to USPTO Patent Public Search; it does not measure application filings, current R&D, or legal strength. Primary class: A61P (Specific Therapeutic Activity OF Chemical Compounds OR Medicinal Preparations).

Compiled by PlainPatent · May 15, 2026

RSS updates for this company

Explore the portfolio See the ranking

The verdict

According to USPTO PatentsView, Shenzhen ranks #33,285 of 49,997 tracked US assignees by granted-patent volume, with 8 patents across 10 technology areas.

#33,285
of 49,997 US assignees by volume: 31st percentile
by Innovation Score (29.6/100): 7.0
avg claims per patent

USPTO PatentsView assignee plate

Corpus R33285 · Foreign Corporation #33,285 · 8 grants

GRANTS-MICRO · MID-PACK · PHOTO-FINISH · CPC-FOCUS · INNOV-THIN · CLAIMS-SPARSE · TYPE-FRNCORP · SPAN-YRS · BOOK-RICH

GRANTS-MICRO 8 grants
MID-PACK #33,285/49,997
PHOTO-FINISH Shenzhen Kuake…
CPC-FOCUS A61P · 10 areas
INNOV-THIN 29.6/100
CLAIMS-SPARSE 7.0 claims/avg
TYPE-FRNCORP Foreign Corp
SPAN-YRS 2020–2025 · 6y
BOOK-RICH 9/10 fields

Nearest grant-volume peer: Shenzhen Kuake Zhichuang Technology Co., Ltd. (±0 grants)

Instrument codes from this assignee’s USPTO PatentsView grant sheet: volume band, corpus rank, photo-finish peer, lead CPC, Innovation Score, claim depth, assignee type, velocity, and book completeness. Not a USPTO rating of patent strength.

How Shenzhen’s 29.6 Innovation Score adds up

The same four weighted components behind every Innovation Score on PlainPatent: portfolio volume, grant velocity, technology breadth, and claim depth.

Volume 7.6 pts (26%) Velocity 6.7 pts (23%) Breadth 11.2 pts (38%) Claim depth 4.2 pts (14%)

Qualcomm Incorporated · highest

85
Shenzhen Profound-Vi… · this assignee

30
3D Lighting… · lowest

7

What this shows Shenzhen's Innovation Score is 29.6/100 (31st percentile of the PatentsView-derived corpus). The chart places that score against the nearest Innovation Score peers plus corpus poles, not a reprint of the volume ranking.

Does more volume mean deeper claims for Shenzhen?

Each dot is one of Shenzhen’s 8 nearest volume peers (same corpus rank neighbourhood as the chart above), placed by total granted patents (horizontal) against average claims per patent (vertical). Shenzhen’s own 7.0 claims/patent is ABOVE the 1.0 median for these volume peers. More thorough claims than most filers at this scale, not just more of them.

Shenzhen vs its 8 nearest volume peers: granted patents vs average claims per patent. Source: USPTO PatentsView.

Where Shenzhen's grants concentrate

Shenzhen Profound-View Pharma Tech Co., Ltd is a focused PatentsView assignee: 10 CPC subclasses with 100% of grants classified under A61P (Specific Therapeutic Activity OF Chemical Compounds OR Medicinal Preparations). Peak complete grant year is 2021 (2 grants) versus a trough of 1 in 2020. By volume, Shenzhen sits between Shenzhen Kuake Zhichuang Technology Co., Ltd. and Shenzhen Weiborui Technology Co., Ltd.

Shenzhen's three-year grant acceleration

Shenzhen Profound-View Pharma Tech Co., Ltd shows 3 grants in 2022–2024 against only 3 in 2019–2021. That prior window is too thin for a growth multiple (rename and spin-out assignees look artificially high when the baseline is near zero), so PlainPatent withholds a ranked acceleration claim here.

Shenzhen Kuake Zh…

8
Shenzhen Le Jia D…

8
Shenzhen Leaderme…

8
Shenzhen Odier Sp…

8
Shenzhen Pukaiyu…

8
Shenzhen Sodi Inn…

8
Shenzhen Tuanxin…

8
Shenzhen Weiborui…

8
Shenzhen Profound… ◀

8

What this shows Shenzhen holds 8 patents at rank #33,376, shown against the 8 assignees closest to it in grant volume rather than the industry's largest filers.

Companies ranked near Shenzhen

By rank, the assignees closest to #33,376 in granted patent volume.

Leaders in A61P (Specific Therapeutic Activity OF Chemical Compounds OR Me…)

Other assignees with the most granted patents in Shenzhen's primary technology class.

Shenzhen's Innovation Score vs. every tracked assignee

Composite of portfolio volume, grant velocity, technology breadth, and claim depth (0–100)

30 31st percentile higher than 31% of 49,997 US assignees

Each bar is a band; taller bars hold more US assignees. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count, share, and where it sits relative to this entry.

Source USPTO PatentsView, PlainPatent Innovation Score · 2015–2025

USPTO utility patent grants by year · 2020–2025

Grants by year

Teal-shaded recent years (2020–present) versus the 2020–2019 baseline. Full figures in the table below.

View data table

Shenzhen Profound-View Pharma Tech Co., Ltd patent grants by year, 2015–2025
Year	Patents Granted	Share of Period
2020	1	12.5%
2021	2	25.0%
2022	1	12.5%
2024	2	25.0%
2025partial year	2	25.0%

Which technologies does Shenzhen Profound-View Pharma Tech Co., Ltd patent most?

A61P - Specific Therapeutic Activity OF Chemical Compounds OR Medicinal Preparations 8

A61K - Preparations FOR Medical, Dental OR Toiletry Purposes 8

C01P - Indexing Scheme Relating TO Structural AND Physical Aspects OF Solid Inorganic Compounds 5

B22F - Working Metallic POWDER; Manufacture OF Articles From Metallic POWDER; Making Metallic Powder ; Apparatus OR Devices Specially Adapted FOR Metallic Powder 5

B82Y - Specific Uses OR Applications OF NANOSTRUCTURES; Measurement OR Analysis OF NANOSTRUCTURES; Manufacture OR Treatment OF Nanostructures 5

C01G - Compounds Containing Metals NOT Covered BY Subclasses C01d OR C01f 5

G01N - Investigating OR Analysing Materials BY Determining Their Chemical OR Physical Properties 5

C22C - Alloys 3

C12N - Microorganisms OR ENZYMES; Compositions THEREOF; Propagating, Preserving, OR Maintaining MICROORGANISMS; Mutation OR Genetic ENGINEERING; Culture Media 3

C08L - Compositions OF Macromolecular Compounds 2

Top 10 of 10 technology areas

More on this record

Data Source

USPTO PatentsView, US granted patents 2015–2025

View all rankings → How is Innovation Score calculated?

What to do with this data

Shenzhen Profound-View Pharma Tech Co., Ltd's patent record in context - here's where to go next.

Shenzhen Profound-View Pharma Tech Co., Ltd's lead technology class is A61P (Specific Therapeutic Activity OF Chemical Compounds OR Medicinal Preparations), 100% of its portfolio - see every assignee active in that class. Explore A61P
Ranked #33,285 of 49,997 tracked assignees by patent volume - see the full leaderboard. See the ranking
Compare Shenzhen Profound-View Pharma Tech Co., Ltd against Shenzhen Kuake Zhichuang Technology Co., Ltd., an assignee filing at a similar volume. Compare portfolios
Innovation Score of 29.6/100 blends volume, velocity, technology breadth, and claim depth. How it's calculated

Figures reflect USPTO PatentsView grant data through May 2026; pending applications not yet granted are not counted.

Data sourced from USPTO PatentsView - official U.S. government patent data. See our methodology for computation details. Retrieved and formatted by PlainPatent

Disclaimer: This information is provided for informational purposes only and does not constitute professional advice. Data is sourced from the USPTO PatentsView database. Consult a qualified professional before making decisions based on this data.

Read our methodology - how this data is sourced, computed, and verified.

Data sources used on this page

USPTO PatentsView - the disambiguated bulk patent-grant, assignee, and CPC data this page's figures are derived from. patentsview.org
Cooperative Patent Classification (CPC) - the joint USPTO/EPO classification scheme used to group patents by technology area. cooperativepatentclassification.org
USPTO Patent Public Search - the official interface to verify the status of any individual patent. ppubs.uspto.gov

Compiled by PlainPatent , US Patent Intelligence Editorial Process · May 15, 2026

Every figure on PlainPatent is rendered directly from USPTO source data, no number is typed in by an editor. This page draws directly on USPTO source data, no figure is typed in by an editor. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error. Data current as of May 2026.